Zobrazeno 1 - 10
of 1 173
pro vyhledávání: ''
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Publikováno v:
Cancer Biomarkers. 31:177-185
BACKGROUND: To investigate the prognostic role of lung immune prognostic index (LIPI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with platinum plus etoposide chemotherapy. METHODS: Data were obtained from two randomized cont
Autor:
Toshihide Yokoyama, Takashi Yokoi, Satoru Miura, Shunsuke Teraoka, Shuji Murakami, Kazushige Wakuda, Yuko Oya, Motohiro Tamiya, Atsushi Nakamura, Takaaki Tokito, Keisuke Tomii, Kenichi Yoshimura, O. Yamaguchi, Nobuyuki Yamamoto, Satoshi Watanabe, Hiroshige Yoshioka, Tetsuhiko Asao, Shoichi Itoh, D. Fujimoto, Akihiro Tamiya, Hiroshi Yokouchi, Koji Haratani
Publikováno v:
European Journal of Cancer. 150:63-72
Introduction Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by t
Publikováno v:
Gastric Cancer
Background This study evaluated the safety and effectiveness of ramucirumab monotherapy and combination therapy for advanced gastric cancer in the real-world setting. Methods This single-arm, prospective, multicenter, non-interventional, observationa
Autor:
John Pollard, Ruth Plummer, Thomas Jeff Evans, Mark R. Middleton, Martin H. Falk, Geoffrey I. Shapiro, Ivan Diaz-Padilla, Bart S. Hendriks, Emma Dean
Publikováno v:
British Journal of Cancer
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib + gemcitabine ± cisplatin
Autor:
Yoko Inaguma, Eiichi Ohtsuka, Yukiyoshi Moriuchi, Kazuho Miyashita, Masashi Mizokami, Nobuhiko Yamauchi, Tadahiko Igarashi, Koji Izutsu, Hiroshi Gomyo, Nobuko Kubota, Ryuzo Ueda, Mio Kurata, Yoshiko Inoue, Yoshiko Atsuta, Rika Sakai, Norifumi Tsukamoto, Yoko Ushijima, Kisato Nosaka, Dai Maruyama, Sachiko Suzuki, Toshiki Uchida, Shinichiro Yoshida, Ilseung Choi, Shigeru Kusumoto, Go Yamamoto, Yasuhito Tanaka, Kensuke Kojima, Satoshi Ichikawa, Hideki Tsujimura
Publikováno v:
Cancer Science
We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received r
Autor:
Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators
Publikováno v:
Leukemia, Vol. 35, no.1, p. 143-155 (2021)
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 36
Autor:
Young Suk Park, Jeeyun Lee, Hyera Kim, Seonggyu Byeon, Jung Yong Hong, Se Hoon Park, Kee-Taek Jang, Won Ki Kang, Joon Oh Park, Seung Tae Kim, Ho Yeong Lim, Jinchul Kim
Publikováno v:
Oncology. 99:365-372
Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhib
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte